Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Nebraska
National Cancer Institute (NCI)
Thomas Jefferson University
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Baylor College of Medicine
Pharmacyclics LLC.
University of Chicago
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
National Institutes of Health Clinical Center (CC)
Dartmouth-Hitchcock Medical Center
Hutchmed
Eli Lilly and Company
Incyte Corporation